Results of the ADRIATIC trial indicated that treatment with Imfinzi after standard-of-care concurrent chemoradiotherapy improves overall survival and progression-free survival in patients with limited-stage small cell lung cancer.
AstraZeneca announced a significant milestone from the ADRIATIC trial, which is evaluating the safety and efficacy of Imfinzi (durvalumab) for the treatment of limited-stage small cell lung cancer (LS-SCLC) in patients who haven’t progressed following concurrent chemoradiotherapycCRT. According to the company, the trial found that administration of Imfinzi after standard-of-care cCRT greatly improves overall survival (OS) and progression-free survival (PFS) compared to placebo. These results were presented at the 2024 American Society of Clinical Oncology Annual Meeting during the Plenary Session.1
“The ADRIATIC results represent a breakthrough in limited-stage small cell lung cancer, a highly aggressive disease where recurrence rates are high and only 15 to 30 per cent of patients survive five years,” said David R. Spigel, chief scientific officer, Sarah Cannon Research Institute, trial investigator, in a press release. “Durvalumab is the first systemic treatment to show improved survival for these patients in decades and should become a new standard of care in this setting.”
The randomized, double-blind, placebo-controlled, multi-center global Phase III ADRIATIC trial trial evaluated Imfinzi monotherapy and Imfinzi plus Imjudo (tremelimumab) versus placebo for 730 patients with LS-SCLC who had not progressed following cCRT. Patients were randomly assigned receive a 1500 mg fixed dose of Imfinzi with or without Imjudo 75 mg every four weeks for up to four doses/cycles each, followed by Imfinzi every four weeks for up to 24 months, or to receive a placebo. The two primary endpoints of the study were PFS and OS for Imfinzi monotherapy versus placebo, with key secondary endpoints including OS and PFS for Imfinzi plus Imjudo versus placebo, as well as safety and quality of life measures.
Results found that compared to placebo, patients treated with Imfinzi experienced a 27% reduction in the risk of death with Imfinzi, with an estimated median OS of 55.9 months versus 33.4 months for placebo. Further, Imfinzi reduced the risk of disease progression or death by 24%, demonstrating a median PFS of 16.6 months compared to 9.2 months for placebo. Other results of the study indicated the following:
GSK reported that the safety profile for Imfinzi was mostly manageable and consistent with previous findings, as no new safety signals were reported. Grade 3-4 adverse events occurred in 24.4% of patients treated with Imfinzi and 24.2% of patients administered placebo.
“The strong improvement in overall survival seen with Imfinzi after concurrent chemoradiotherapy is transformative in the treatment of limited-stage small cell lung cancer. These tremendous results underscore our ambition to drive up survival rates in this earlier-stage lung cancer setting, and we look forward to working with regulatory authorities to bring Imfinzi to these patients as quickly as possible,” said Susan Galbraith, EVP, Oncology R&D, AstraZeneca, in the press release.
Reference
Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo. AstraZeneca. June 2, 2024. Accessed June 3, 2024. https://www.astrazeneca.com/media-centre/press-releases/2024/imfinzi-is-first-and-only-immunotherapy-to-show-survival-benefit-in-limited-stage-small-cell-lung-cancer-in-global-phase-iii-trial.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.